[
  {
    "ts": null,
    "headline": "Walmart Stock Rallies, Pushing Market Cap Above $900 Billion",
    "summary": "Walmart's market value closed above a $900 billion for the first time on Wednesday. The retailer’s stock rose 1.8%, making it the 12th U.S. company to surpass the milestone, according to Dow Jones Market Data.",
    "url": "https://finnhub.io/api/news?id=eb40673094d3dd4562cdfe52f4f41a2bc39b34be91f39af1fa416f82d4ac32d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764799124,
      "headline": "Walmart Stock Rallies, Pushing Market Cap Above $900 Billion",
      "id": 137677594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Walmart's market value closed above a $900 billion for the first time on Wednesday. The retailer’s stock rose 1.8%, making it the 12th U.S. company to surpass the milestone, according to Dow Jones Market Data.",
      "url": "https://finnhub.io/api/news?id=eb40673094d3dd4562cdfe52f4f41a2bc39b34be91f39af1fa416f82d4ac32d0"
    }
  },
  {
    "ts": null,
    "headline": "As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?",
    "summary": "Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.",
    "url": "https://finnhub.io/api/news?id=28cda45827c416ae43d0b337a13ec4f83b9f51e8b4bf0214f916b7b1cc7770ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764789262,
      "headline": "As Eli Lilly Cuts Zepbound Prices, Should You Buy, Sell, or Hold LLY Stock?",
      "id": 137677749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has decided to slash prices of its weight loss drug Zepbound, making it more accessible to customers.",
      "url": "https://finnhub.io/api/news?id=28cda45827c416ae43d0b337a13ec4f83b9f51e8b4bf0214f916b7b1cc7770ff"
    }
  },
  {
    "ts": null,
    "headline": "1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year",
    "summary": "A key catalyst may be right around the corner.",
    "url": "https://finnhub.io/api/news?id=13901bd9a393ae2115d256159ad34f2b23845ef2a574c61cdfa98bc737778130",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786600,
      "headline": "1 Reason to Buy Eli Lilly Hand Over Fist Before the New Year",
      "id": 137677750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A key catalyst may be right around the corner.",
      "url": "https://finnhub.io/api/news?id=13901bd9a393ae2115d256159ad34f2b23845ef2a574c61cdfa98bc737778130"
    }
  },
  {
    "ts": null,
    "headline": "U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts",
    "url": "https://finnhub.io/api/news?id=89193a04825a5063668dda8dcb8df9472a8117349940ad675c38aa5ba581f7a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764784740,
      "headline": "U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor",
      "id": 137677751,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts",
      "url": "https://finnhub.io/api/news?id=89193a04825a5063668dda8dcb8df9472a8117349940ad675c38aa5ba581f7a5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=a5ae074ecce8b5cc12909b164804ab876e19b61d1910a1a4d0fd3c5f88f50f00",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779460,
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "id": 137681381,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a5ae074ecce8b5cc12909b164804ab876e19b61d1910a1a4d0fd3c5f88f50f00"
    }
  },
  {
    "ts": null,
    "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
    "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
    "url": "https://finnhub.io/api/news?id=7f3a74107aeafcaabdcacaa5cd253e51b2ff148f09a335477dc214936b52ae82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764771960,
      "headline": "Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?",
      "id": 137672736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.",
      "url": "https://finnhub.io/api/news?id=7f3a74107aeafcaabdcacaa5cd253e51b2ff148f09a335477dc214936b52ae82"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca",
    "summary": "Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca",
    "url": "https://finnhub.io/api/news?id=53eddef96108a97c9f239a08e58f39891b8606191509c6f4e7db798a60214ef5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764768180,
      "headline": "Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca",
      "id": 137681382,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly Gets Expanded FDA Approval for Cancer Drug Jaypirca",
      "url": "https://finnhub.io/api/news?id=53eddef96108a97c9f239a08e58f39891b8606191509c6f4e7db798a60214ef5"
    }
  },
  {
    "ts": null,
    "headline": "Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do",
    "summary": "NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.",
    "url": "https://finnhub.io/api/news?id=d7b6690c51fbb019238aad330ec30866b9264fea9c96908bde93677eec4186c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764766800,
      "headline": "Excelsior Sciences Raises $95 Million to Transform Small Molecule Discovery and Manufacturing with Novel Chemistry that Machines Can Do",
      "id": 137670998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK, December 03, 2025--Excelsior Sciences, a company developing a new form of chemistry that machines can do and AI can use to enable closed-loop drug discovery, today announced it has raised $95 million to accelerate its mission to reinvent the process of discovering and manufacturing small molecules.",
      "url": "https://finnhub.io/api/news?id=d7b6690c51fbb019238aad330ec30866b9264fea9c96908bde93677eec4186c0"
    }
  },
  {
    "ts": null,
    "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
    "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
    "url": "https://finnhub.io/api/news?id=dd62313fe6e190659e08c0a4b422f1fce66c4b81cf03b38bb9a8ba1c04e728cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764764781,
      "headline": "Tech Is Getting Left Behind in the S&P 500’s Latest Rebound",
      "id": 137670999,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Co, Cardinal Health Inc. and Biogen Inc. are among the top 10 performers in the S&P 500 since Oct. 28, the last time the index closed at a record.  In contrast, the S&P 500 Information Technology index is down 4.2% since then, with bigger losses coming from Magnificent Seven stocks like Nvidia Corp. and Microsoft Corp.  The moves suggest that investor are still skittish about the artificial intelligence trade as concerns linger about valuations and whether all the heavy spending on computing power will pay off with profits.",
      "url": "https://finnhub.io/api/news?id=dd62313fe6e190659e08c0a4b422f1fce66c4b81cf03b38bb9a8ba1c04e728cd"
    }
  },
  {
    "ts": null,
    "headline": "2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years",
    "summary": "They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.",
    "url": "https://finnhub.io/api/news?id=0ddb22eadfbe7db99e4039ed66f17621d211a5af6f0e2b6887f9211369929ad1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764762300,
      "headline": "2 Trillion-Dollar Dividend Stocks to Buy and Hold for 10 Years",
      "id": 137671000,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "They are capitalizing on their ability to innovate and rewarding loyal shareholders in the process.",
      "url": "https://finnhub.io/api/news?id=0ddb22eadfbe7db99e4039ed66f17621d211a5af6f0e2b6887f9211369929ad1"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains",
    "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]",
    "url": "https://finnhub.io/api/news?id=68f64ccc0f57e1b37032a18f231c9b3098a6d7ef464717ef4dd0198b20fa75bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764745056,
      "headline": "Bernstein Reaffirms Price Target on Eli Lilly (LLY) After Breakthrough Gains",
      "id": 137667570,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly & Company (NYSE:LLY) ranks among the Best Low Volatility Investments in December 2025. Eli Lilly & Company (NYSE:LLY) reached another milestone on November 21, becoming the first drugmaker to join the exclusive $1 trillion club populated by tech behemoths and cementing its position as a weight-loss powerhouse. The company’s stock has rallied more […]",
      "url": "https://finnhub.io/api/news?id=68f64ccc0f57e1b37032a18f231c9b3098a6d7ef464717ef4dd0198b20fa75bc"
    }
  }
]